Are targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?

Metastatic pancreatic ductal adenocarcinoma (PDAC) is a major health burden due to its increasing incidence and poor prognosis. PDAC is characterized by a low tumor mutational burden, and its molecular pathogenesis is driven by Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations. Response to...

Descripción completa

Detalles Bibliográficos
Autores principales: Rémond, M.S., Pellat, A., Brezault, C., Dhooge, M., Coriat, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674888/
https://www.ncbi.nlm.nih.gov/pubmed/36399952
http://dx.doi.org/10.1016/j.esmoop.2022.100638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674888/
https://www.ncbi.nlm.nih.gov/pubmed/36399952
http://dx.doi.org/10.1016/j.esmoop.2022.100638

Ejemplares similares